This page lists the SEC filings reported by Orbimed Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2023-09-21 | ORBIMED ADVISORS LLC | Ikena Oncology, Inc. | 2,189,111 | 5.2% | EDGAR |
| SC 13D/A | 2023-09-18 | ORBIMED ADVISORS LLC | Galecto, Inc. | 749,557 | 2.8% | EDGAR |
| SC 13D/A | 2023-09-14 | ORBIMED ADVISORS LLC | Ikena Oncology, Inc. | 2,342,232 | 5.5% | EDGAR |
| SC 13D/A | 2023-09-05 | ORBIMED ADVISORS LLC | Galecto, Inc. | 1,149,694 | 4.2% | EDGAR |
| SC 13D/A | 2023-08-23 | ORBIMED ADVISORS LLC | PMV Pharmaceuticals, Inc. | 6,563,077 | 13.5% | EDGAR |
| SC 13D/A | 2023-08-17 | ORBIMED ADVISORS LLC | Galecto, Inc. | 1,607,579 | 5.9% | EDGAR |
| SC 13D/A | 2023-08-11 | ORBIMED ADVISORS LLC | Gracell Biotechnologies Inc. | 7,641,531 | 8.0% | EDGAR |
| SC 13D/A | 2023-08-03 | ORBIMED ADVISORS LLC | Xtant Medical Holdings, Inc. | 73,114,592 | 56.7% | EDGAR |
| SC 13D/A | 2023-08-02 | ORBIMED ADVISORS LLC | Galecto, Inc. | 2,241,440 | 8.3% | EDGAR |
| SC 13D | 2023-07-24 | ORBIMED ADVISORS LLC | Turnstone Biologics Corp. | 3,099,265 | 13.4% | EDGAR |
| SC 13D/A | 2023-07-19 | ORBIMED ADVISORS LLC | Theseus Pharmaceuticals, Inc. | 17,713,600 | 40.7% | EDGAR |
| SC 13D/A | 2023-07-17 | ORBIMED ADVISORS LLC | Galecto, Inc. | 2,455,640 | 9.6% | EDGAR |
| SC 13D/A | 2023-06-29 | ORBIMED ADVISORS LLC | Adicet Bio, Inc. | 6,647,598 | 15.5% | EDGAR |
| SC 13D/A | 2023-06-29 | ORBIMED ADVISORS LLC | Passage BIO, Inc. | 8,034,000 | 14.7% | EDGAR |
| SC 13D/A | 2023-06-21 | ORBIMED ADVISORS LLC | Disc Medicine, Inc. | 2,269,637 | 10.2% | EDGAR |
| SC 13D/A | 2023-05-24 | ORBIMED ADVISORS LLC | Prelude Therapeutics Inc | 15,716,642 | 28.6% | EDGAR |
| SC 13D | 2023-05-24 | ORBIMED ADVISORS LLC | VectivBio Holding AG | 5,156,561 | 7.7% | EDGAR |
| SC 13D/A | 2023-05-17 | ORBIMED ADVISORS LLC | SpringWorks Therapeutics, Inc. | 4,178,588 | 6.7% | EDGAR |
| SC 13D/A | 2023-05-16 | ORBIMED ADVISORS LLC | Verona Pharma plc | 3,777,778 | 4.8% | EDGAR |
| SC 13D/A | 2023-05-16 | ORBIMED ADVISORS LLC | Fusion Pharmaceuticals Inc. | 2,930,670 | 4.6% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.